Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Franca Fruzzetti, Florence Trémollieres & Johannes Bitzer. (2012) An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecological Endocrinology 28:5, pages 400-408.
Read now
Read now
Alı R. Odabaşi, Mert Küçük, Hasan Yüksel, Zekerıya Güner & Selda D. Sezer. (2011) Effects of two different low-dose oral contraceptives on plasma homocysteine levels. Gynecological Endocrinology 27:3, pages 176-179.
Read now
Read now
Diana Mansour, Pirjo Inki & Kristina Gemzell-Danielsson. (2010) Efficacy of contraceptive methods: A review of the literature. The European Journal of Contraception & Reproductive Health Care 15:1, pages 4-16.
Read now
Read now
Susan Zeun, Ming Lu, Alkaz Uddin, Brian Zeiler, Dennis Morrison & Hartmut Blode. (2009) Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. The European Journal of Contraception & Reproductive Health Care 14:3, pages 221-232.
Read now
Read now
J Endrikat, J Wessel, P Rosenbaum & B Düsterberg. (2004) Plasma concentrations of endogenous hormones during one regular treatment cycle with a low-dose oral contraceptive and during two cycles with deliberate omission of two tablets. Gynecological Endocrinology 18:6, pages 318-326.
Read now
Read now
J. Endrikat, C. Gerlinger, K. Plettig, J. Wessel, W. Schmidt, G. Grubb & B. Düsterberg. (2003) A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use. Gynecological Endocrinology 17:2, pages 107-114.
Read now
Read now
M. Vree. (2002) Lower hormone dosage with improved cycle control. The European Journal of Contraception & Reproductive Health Care 7:sup2, pages 25-30.
Read now
Read now
J. Endrikat, H. Blode, C. Gerlinger, P. Rosenbaum & W. Kuhnz. (2002) A pharmacokinetic study with a low-dose oral contraceptive containing 20 μg ethinylestradiol plus 100 μg levonorgestrel. The European Journal of Contraception & Reproductive Health Care 7:2, pages 79-90.
Read now
Read now
J. Endrikat, C. Gerlinger, M. Cronin, J. Wessel, A. Ruebig, P. Rosenbaum & B. Düsterberg. (2001) Body weight change during use of a monophasic oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene with a comparison of the women who completed versus those who prematurely discontinued
intake
. The European Journal of Contraception & Reproductive Health Care 6:4, pages 199-204.
Read now
Read now
J. Endrikat, C. Gerlinger, M. Cronin, A. Ruebig, W. Schmidt & B. Düsterberg. (2001) Blood pressure stability in a normotensive population during intake of a monophasic oral contraceptive containing 20 μg ethinylestradiol and 75 g gestodene. The European Journal of Contraception & Reproductive Health Care 6:3, pages 159-166.
Read now
Read now
. (1999) The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 µg and ethinylestradiol 15 µg. The European Journal of Contraception & Reproductive Health Care 4:sup2, pages 9-15.
Read now
Read now
H. P. Oosterbaan. (1999) An open-label study of the effects of a 24-day regimen of gestodene 60 µg/ethinylestradiol 15 µg on endometrial histological findings in healthy women. The European Journal of Contraception & Reproductive Health Care 4:sup2, pages 3-8.
Read now
Read now
R. C. Hite, R. Bannemerschult, P. Fox-Kuchenbecker, R. Turck & K. Brill. (1999) Large observational trial of a new low-dose oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel (Miranovar`) in Germany. The European Journal of Contraception & Reproductive Health Care 4:1, pages 7-13.
Read now
Read now
D. Serfaty & M. L. Vree. (1998) A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene. The European Journal of Contraception & Reproductive Health Care 3:4, pages 179-189.
Read now
Read now
Articles from other publishers (25)
PAMELA A. ROYER & KIRTLY P. JONES. (2014) Progestins for Contraception. Clinical Obstetrics & Gynecology 57:4, pages 644-658.
Crossref
Crossref
F. Trémollieres. (2012) Contraception orale estro-progestative : quelle différence entre éthinylestradiol et estradiol ?. Gynécologie Obstétrique & Fertilité 40:2, pages 109-115.
Crossref
Crossref
Leena Anttila, Gloria Bachmann, László Hernádi, Michael Kunz, Joachim Marr & Christine Klipping. (2011) Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. European Journal of Obstetrics & Gynecology and Reproductive Biology 155:2, pages 180-182.
Crossref
Crossref
Franca Fruzzetti & Johannes Bitzer. (2010) Review of clinical experience with estradiol in combined oral contraceptives. Contraception 81:1, pages 8-15.
Crossref
Crossref
Jan Endrikat, Susanne Parke, Dietmar Trummer, Werner Schmidt, Ingrid Duijkers & Christine Klipping. (2008) Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 78:3, pages 218-225.
Crossref
Crossref
Ione C. Barbosa, Carlos Isaia Filho, Dirceu FaggionJr.Jr. & Edmund Chada Baracat. (2006) Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 μg and ethinylestradiol 15 μg (Minesse®). Contraception 73:1, pages 30-33.
Crossref
Crossref
Jørgen Jespersen, Jan Endrikat, Bernd Düsterberg, Werner Schmidt, Christoph Gerlinger, Jens Wessel, Johannes J. Sidelmann & Sven O. Skouby. (2005) A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 μg of ethinylestradiol and 100 μg of levonorgestrel with 30 μg of ethinylestradiol and 100 μg of levonorgestrel. Contraception 72:2, pages 98-104.
Crossref
Crossref
Sven O. Skouby, Jan Endrikat, Bernd Düsterberg, Werner Schmidt, Christoph Gerlinger, Jens Wessel, Henri Goldstein & Joergen Jespersen. (2005) A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel. Contraception 71:2, pages 111-117.
Crossref
Crossref
N.R de Melo, J.M Aldrighi, D FaggionJr.Jr., V.R.O.Y Reyes, J.B Souza, C.E Fernandes & E Larson. (2004) A prospective open-label study to evaluate the effects of the oral contraceptive Harmonet? (gestodene75/EE20) on body fat. Contraception 70:1, pages 65-71.
Crossref
Crossref
J. Endrikat, E. Mih, B. Düsterberg, K. Land, C. Gerlinger, W. Schmidt & D. Felsenberg. (2004) A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 μg or 30 μg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception 69:3, pages 179-187.
Crossref
Crossref
M. BRINCAT, Y. MUSCAT BARON & R. GALEA. (2003) How Low Can You Get?. Annals of the New York Academy of Sciences 997:1, pages 158-162.
Crossref
Crossref
Susana Bassol, Gloria Alvarado, Ranferi Gaona Arreola, Cuauhtemoc Celis-Gonzalez, Efrain Perez Pe?a, Josue Garza Flores, Jose R. Ahued, Roger Lara Ricalde, Carlos R. Lopez, Gustavo Prieto, Carlos Gurucharri, Monica G. Heredia, Oscar Contreras Ortiz, Gabriela Percossi, Pedro R. Figueroa Casas, Elida Botto, Roberto Italo Tozzini, Gustavo Botti, Anibal Nu?ez de Pierro, Mirta Fernandez, Enrique Lastreto, Monica ?a?ez, Hildoberto Carneiro de Oliveira, Martha E. Diogenes Holanda Yazlle, Jaime Silva, German Salazar, Jorge Gomez, Gloria Penagos, Rodrigo Cifuentes, Luz A. Torres, Roberto Reyes-Marquez & Gerhard Albrecht. (2003) A 13-month multicenter clinical experience of a low-dose monophasic oral contraceptive containing 20 ?g ethinylestradiol and 75 ?g gestodene in Latin American women. Contraception 67:5, pages 367-372.
Crossref
Crossref
Susan J. Keam & Antona J. Wagstaff. (2003) Ethinylestradiol/Drospirenone. Treatments in Endocrinology 2:1, pages 49-70.
Crossref
Crossref
J. Endrikat, C. Klipping, M. Cronin, C. Gerlinger, A. Ruebig, W. Schmidt & B. Düsterberg. (2002) An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 65:3, pages 215-221.
Crossref
Crossref
J. Endrikat, C. Klipping, C. Gerlinger, A. Ruebig, W. Schmidt, T. Holler & B. Düsterberg. (2001) A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 30 μg ethinyl estradiol and 75 μg gestodene on hemostatic variables, lipids, and carbohydrate metabolism. Contraception 64:4, pages 235-241.
Crossref
Crossref
J. Endrikat, M. Cronin, C. Gerlinger, A. Ruebig, W. Schmidt & B. Düsterberg. (2001) Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 20 μg ethinyl estradiol and 150 μg desogestrel. Contraception 64:3, pages 201-207.
Crossref
Crossref
J. Endrikat, M. Cronin, C. Gerlinger, A. Ruebig, W. Schmidt & B. Düsterberg. (2001) Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 μg ethinyl estradiol and 75 μg gestodene. Contraception 64:2, pages 99-105.
Crossref
Crossref
J. Endrikat, R. Hite, R. Bannemerschult, C. Gerlinger & W. Schmidt. (2001) Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 μg ethinylestradiol/100 μg levonorgestrel and 20 μg ethinylestradiol/500 μg norethisterone. Contraception 64:1, pages 3-10.
Crossref
Crossref
Alfred Poindexter. (2001) The emerging use of the 20-μg oral contraceptive. Fertility and Sterility 75:3, pages 457-465.
Crossref
Crossref
S. Bassol, A. Alvarado, C. Celis, M.C. Cravioto, O. Peralta, R. Montaño, J. Novelli, H. Albornoz, E. Kesseru, A. Soares, A. Petracco, B. Isaia, J. Mendes, L. Bahamondes, N.R. de Melo, R. Reyes-Marquez & G. Albrecht. (2000) Latin American experience with two low–dose oral contraceptives containing 30 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel. Contraception 62:3, pages 131-135.
Crossref
Crossref
Melonie Burrows & Steve Bird. (2000) The Physiology of the Highly Trained Female Endurance Runner. Sports Medicine 30:4, pages 281-300.
Crossref
Crossref
J Endrikat, B Düsterberg, A Ruebig, C Gerlinger & T Strowitzki. (1999) Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 60:5, pages 269-274.
Crossref
Crossref
K. Bennell, S. White & K. Crossley. (1999) The oral contraceptive pill: a revolution for sportswomen?. British Journal of Sports Medicine 33:4, pages 231-238.
Crossref
Crossref
R. Bannemerschult, J.P. Hanker, C. Wünsch, P. Fox, M. Albring & K. Brill. (1997) A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles. Contraception 56:5, pages 285-290.
Crossref
Crossref
J. Endrikat, U. M?ller & B. D?sterberg. (1997) A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 ?g ethinylestradiol/75 ?g gestodene and 30 ?g ethinylestradiol/75 ?g gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 55:3, pages 131-137.
Crossref
Crossref